PD-205520

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NamePD-205520

Drug Alias NameERB-B tyrosine kinase receptor inhibitor (Pfizer)PD-205520

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonistsReceptor protein-tyrosine kinase erbB-4 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3Receptor protein-tyrosine kinase erbB-4

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Global Research and Development

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Global Research and Development

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A